Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Completed · Phase 2

Conditions studied: Glaucoma, Open-Angle, Ocular Hypertension

In brief

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

Key facts

Study ID

NCT01001195

Run by

Allergan

People needed

165

Starts

2009-11-01

Expected to finish

2010-04-01

Last updated by the study team

2013-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or primary open-angle glaucoma in each eye
• Patient requires IOP lowering medication in each eye

You may not qualify if…

• Ocular hyperemia or other ocular surface findings in either eye
• Active ocular disease
• Current or anticipated use of any topical ocular medication (including artificial tears) during the study
• Intraocular surgery within past six months or unilateral cataract surgery.
• Functionally significant visual field loss
• Anticipated wearing of contact lenses during study
• Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit

Where it is running

• Study site — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.